

US Family Health Plan

Prior Authorization Request Form for efinaconazole (**Jublia**) and tavaborole (**Kerydin**)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be **faxed to 855-273-5735**
OR

The patient may attach the completed form to the prescription and mail it to:
Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? Call 1-877-880-7007

Prior Authorization expires after one year.

usfamilyhealth.org/rx-pa

Step 1 Please complete patient and physician information (please print):

Patient Name: _____	Physician Name: _____
Address: _____	Address: _____
Sponsor ID # _____	Phone #: _____
Date of Birth: _____	Secure Fax #: _____

Step 2 Please complete the clinical assessment:

1. Does the patient have a diagnosis of onychomycosis?	<input type="checkbox"/> Yes Proceed to question 2	<input type="checkbox"/> No Coverage not approved
2. Is the diagnosis of onychomycosis confirmed by either KOH preparation, fungal culture, nail biopsy, OR another assessment to confirm the diagnosis?	<input type="checkbox"/> Yes Proceed to question 3	<input type="checkbox"/> No Coverage not approved
3. Is the patient immunocompromised, or has a diagnosis of diabetes mellitus or peripheral vascular disease?	<input type="checkbox"/> Yes Proceed to question 4	<input type="checkbox"/> No Coverage not approved
4. Is there pain in the affected nail(s) or swelling and/or redness in the surrounding nail tissue?	<input type="checkbox"/> Yes Proceed to question 5	<input type="checkbox"/> No Coverage not approved
5. Has the patient tried and experienced therapeutic failure to ciclopirox (Penlac)?	<input type="checkbox"/> Yes Proceed to question 6	<input type="checkbox"/> No Coverage not approved
6. Has the patient tried and experienced therapeutic failure to itraconazole (Sporonox) or terbinafine (Lamisil)?	<input type="checkbox"/> Yes SKIP to question 9	<input type="checkbox"/> No Proceed to question 7
7. Does the patient have a contraindication (such as renal impairment, pre-existing liver disease, or evidence of ventricular dysfunction, such as CHF) to itraconazole (Sporonox) OR terbinafine (Lamisil)?	<input type="checkbox"/> Yes SKIP to question 9	<input type="checkbox"/> No Proceed to question 8
8. Has the patient experienced an adverse event or intolerance to itraconazole (Sporonox) OR terbinafine (Lamisil)?	<input type="checkbox"/> Yes Proceed to question 9	<input type="checkbox"/> No Coverage not approved
9. Is treatment being requested due to a medical condition and not for cosmetic purposes? <i>(Note: examples of a medical condition include the following: patients with a history of cellulitis of the lower extremity who have ipsilateral toenail onychomycosis; diabetic patients with additional risk factors for cellulitis; patients who experience pain/discomfort associated with the infected nail)</i>	<input type="checkbox"/> Yes Proceed to question 10	<input type="checkbox"/> No Coverage not approved
10. Is the patient's condition causing debility or disruption in their activities of daily living?	<input type="checkbox"/> Yes Proceed to question 11 on page 2	<input type="checkbox"/> No Coverage not approved

Prior Authorization Request Form for
efinaconazole (**Jublia**) and tavaborole (**Kerydin**)

11. Has the patient had a previous trial of Jublia or Kerydin?	<input type="checkbox"/> Yes Proceed to question 12	<input type="checkbox"/> No Sign and date below
12. Has the patient used Jublia or Kerydin within the previous 24 months?	<input type="checkbox"/> Yes Proceed to question 13	<input type="checkbox"/> No Coverage not approved
13. Has the patient completed a full course of therapy with Jublia or Kerydin within the previous 30 days?	<input type="checkbox"/> Yes Sign and date below	<input type="checkbox"/> No Coverage not approved

Step I certify the above is true to the best of my knowledge. Please sign and date:

3

Prescriber Signature

Date

[10 August 2016]